Back to results
US 12,584,130 B2Granted
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsDonald Foster, Gregory Hinkle, Mark K. Schlegel
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
Claims36
A double stranded ribonucleic acid (dsRNA) agent, or a salt thereof, for inhibiting expression of angiotensinogen (AGT),
- wherein the dsRNA agent, or a salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,
- wherein the sense strand comprises at least 19 contiguous nucleotides from the nucleotide sequence 5′-gsuscaucCfaCfAfAfugagaguaca-3′ (SEQ ID NO:482) and the antisense strand comprises at least 19 contiguous nucleotides from the nucleotide sequence 5′-usGfsuac(Tgn)cucauugUfgGfaugacsgsa-3′ (SEQ ID NO:666),
- wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, G, C, and U, respectively;
- Af, Gf, Cf and Uf are 2′-fluoro A, G, C and U, respectively;
- s is a phosphorothioate linkage;
- and (Tgn) is a thymidine-glycol nucleic acid (GNA) S-Isomer.
3 more elements
Dependencies are inferred from the claim text.